These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 16642769

  • 1. Selection of foot and mouth disease vaccine strains--a review.
    Paton DJ, Valarcher JF, Bergmann I, Matlho OG, Zakharov VM, Palma EL, Thomson GR.
    Rev Sci Tech; 2005 Dec; 24(3):981-93. PubMed ID: 16642769
    [Abstract] [Full Text] [Related]

  • 2. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals.
    Grubman MJ.
    Biologicals; 2005 Dec; 33(4):227-34. PubMed ID: 16289996
    [Abstract] [Full Text] [Related]

  • 3. Foot-and-mouth disease vaccine potency testing in cattle using homologous and heterologous challenge strains: precision of the "Protection against Podal Generalisation" test.
    Goris N, Maradei E, D'Aloia R, Fondevila N, Mattion N, Perez A, Smitsaart E, Nauwynck HJ, La Torre J, Palma E, De Clercq K.
    Vaccine; 2008 Jun 25; 26(27-28):3432-7. PubMed ID: 18499310
    [Abstract] [Full Text] [Related]

  • 4. Some guidelines for determining foot-and-mouth disease vaccine strain matching by serology.
    Mattion N, Goris N, Willems T, Robiolo B, Maradei E, Beascoechea CP, Perez A, Smitsaart E, Fondevila N, Palma E, De Clercq K, La Torre J.
    Vaccine; 2009 Jan 29; 27(5):741-7. PubMed ID: 19041355
    [Abstract] [Full Text] [Related]

  • 5. Reintroduction of foot-and-mouth disease in Argentina: characterisation of the isolates and development of tools for the control and eradication of the disease.
    Mattion N, König G, Seki C, Smitsaart E, Maradei E, Robiolo B, Duffy S, León E, Piccone M, Sadir A, Bottini R, Cosentino B, Falczuk A, Maresca R, Periolo O, Bellinzoni R, Espinoza A, Torre JL, Palma EL.
    Vaccine; 2004 Oct 22; 22(31-32):4149-62. PubMed ID: 15474705
    [Abstract] [Full Text] [Related]

  • 6. Updating of the correlation between lpELISA titers and protection from virus challenge for the assessment of the potency of polyvalent aphtovirus vaccines in Argentina.
    Maradei E, La Torre J, Robiolo B, Esteves J, Seki C, Pedemonte A, Iglesias M, D'Aloia R, Mattion N.
    Vaccine; 2008 Dec 02; 26(51):6577-86. PubMed ID: 18835312
    [Abstract] [Full Text] [Related]

  • 7. Effect of emergency FMD vaccine antigen payload on protection, sub-clinical infection and persistence following direct contact challenge of cattle.
    Cox SJ, Voyce C, Parida S, Reid SM, Hamblin PA, Hutchings G, Paton DJ, Barnett PV.
    Vaccine; 2006 Apr 12; 24(16):3184-90. PubMed ID: 16488060
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Quality assurance/quality control of foot and mouth disease solid phase competition enzyme-linked immunosorbent assay--Part I. Quality assurance: development of secondary and working standards.
    Goris N, De Clercq K.
    Rev Sci Tech; 2005 Dec 12; 24(3):995-1004. PubMed ID: 16642770
    [Abstract] [Full Text] [Related]

  • 10. High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus.
    Brehm KE, Kumar N, Thulke HH, Haas B.
    Vaccine; 2008 Mar 20; 26(13):1681-7. PubMed ID: 18313814
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Production and application of recombinant antibodies to foot-and-mouth disease virus non-structural protein 3ABC.
    Foord AJ, Muller JD, Yu M, Wang LF, Heine HG.
    J Immunol Methods; 2007 Apr 10; 321(1-2):142-51. PubMed ID: 17328909
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rapid methodology for antigenic profiling of FMDV field strains and for the control of identity, purity and viral integrity in commercial virus vaccines using monoclonal antibodies.
    Seki C, Robiolo B, Periolo O, Iglesias M, D'Antuono A, Maradei E, Barros V, La Torre J, Mattion N.
    Vet Microbiol; 2009 Jan 13; 133(3):239-51. PubMed ID: 18774662
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Presence of antibodies to non-structural proteins of foot-and-mouth disease virus in repeatedly vaccinated cattle.
    Lee F, Jong MH, Yang DW.
    Vet Microbiol; 2006 Jun 15; 115(1-3):14-20. PubMed ID: 16446061
    [Abstract] [Full Text] [Related]

  • 17. Induction of protective immunity in swine by immunization with live attenuated recombinant pseudorabies virus expressing the capsid precursor encoding regions of foot-and-mouth disease virus.
    Li X, Liu R, Tang H, Jin M, Chen H, Qian P.
    Vaccine; 2008 May 23; 26(22):2714-22. PubMed ID: 18436351
    [Abstract] [Full Text] [Related]

  • 18. Marker vaccine potential of a foot-and-mouth disease virus with a partial VP1 G-H loop deletion.
    Fowler VL, Knowles NJ, Paton DJ, Barnett PV.
    Vaccine; 2010 Apr 26; 28(19):3428-34. PubMed ID: 20199761
    [Abstract] [Full Text] [Related]

  • 19. Avidity and subtyping of specific antibodies applied to the indirect assessment of heterologous protection against Foot-and-Mouth Disease Virus in cattle.
    Lavoria MÁ, Di-Giacomo S, Bucafusco D, Franco-Mahecha OL, Pérez-Filgueira DM, Capozzo AV.
    Vaccine; 2012 Nov 06; 30(48):6845-50. PubMed ID: 23000129
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.